Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor

Toxicol Appl Pharmacol. 2017 Sep 1:330:65-73. doi: 10.1016/j.taap.2017.07.006. Epub 2017 Jul 12.

Abstract

Heat shock protein 90 (Hsp90) is a critically conserved molecular chaperone protein and promising therapeutic target for cancer treatment. In this study, platycodin D (PD), a saponin isolated from traditional Chinese herb Platycodonis Radix, was identified as a novel Hsp90 inhibitor. We verified that PD did not affect the ATPase activity of Hsp90. However, PD disrupted the co-chaperone interaction of Hsp90/cell division cycle protein 37 (Cdc37) and subsequently degraded multiple Hsp90 client proteins without the feedback increase of Hsp70. In different genotypes of non-small cell lung cancer cells, co-treatment with the mTOR inhibitor Everolimus and PD enhanced antiproliferation activity and apoptotic effect. The feedback survival signal upon mTOR inhibition was fully terminated by the co-administration with PD through reduced epidermal growth factor receptor (EGFR) and insulin growth factor 1 receptor (IGF1R) expression, suppressed AKT activity, and reinforced 4E-BP1 inhibition. Our results not only identified PD as a novel Hsp90 inhibitor by disrupting the protein-protein interaction of Hsp90/Cdc37 complex, but also provided mechanistic insights into the ineffectiveness of mTOR inhibitors and identified therapeutic strategy for cancer treatment.

Keywords: Cdc37; EGFR; Everolimus; Hsp90; IGF1R; Platycodin D.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Cell Cycle Proteins / drug effects*
  • Cell Proliferation / drug effects
  • Chaperonins / drug effects*
  • ErbB Receptors / antagonists & inhibitors
  • Everolimus / pharmacology
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Oncogene Protein v-akt / antagonists & inhibitors
  • Receptor, IGF Type 1
  • Receptors, Somatomedin / antagonists & inhibitors
  • Saponins / toxicity*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • Triterpenes / toxicity*

Substances

  • Antineoplastic Agents
  • CDC37 protein, human
  • Cell Cycle Proteins
  • HSP90 Heat-Shock Proteins
  • IGF1R protein, human
  • Immunosuppressive Agents
  • Receptors, Somatomedin
  • Saponins
  • Triterpenes
  • Everolimus
  • platycodin D
  • EGFR protein, human
  • ErbB Receptors
  • Receptor, IGF Type 1
  • Oncogene Protein v-akt
  • TOR Serine-Threonine Kinases
  • Chaperonins